Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27566402 | 0.98 | HCAR2 (0.44) | HCAR2NAPRTATMAPLNRNAMPT | |
| SCHEMBL5082291 | 0.84 | NAPRT (0.54) | NAPRTAPLNRPTGS2KDM4ESMN1; SMN2 | |
| Sulfuric Acid SCHEMBL4272206 | 0.81 | HCAR2 (0.52) | HCAR2ATMAPLNRNAMPTCYP11B1 | |
| SCHEMBL1641957 | 0.80 | PTGS2 (0.44) | HCAR2ATMAPLNRCYP11B1CYP11B2 | |
| SCHEMBL10749776 | 0.79 | ATM (0.50) | HCAR2ATMAPLNRNAMPTCYP11B1 | |
| SCHEMBL5149401 | 0.78 | APLNR (0.59) | HCAR2ATMAPLNRPTGS2KDM4E | |
| SCHEMBL1826904 | 0.78 | HCAR2 (0.41) | HCAR2ATMAPLNRNAMPTCYP11B1 | |
| SCHEMBL31028721 | 0.78 | APLNR (0.59) | HCAR2ATMAPLNRPTGS2KDM4E | |
| SCHEMBL31050394 | 0.77 | PTGS2 (0.40) | HCAR2ATMAPLNRNAMPTCYP11B1 | |
| Hydrochloric Acid SCHEMBL28569222 | 0.77 | HCAR2 (0.39) | HCAR2ATMAPLNRNAMPTCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105088311-B | A kind of aluminium alloy is without nickel environmental protection hole sealing agent | 深圳前海艾丽优科技有限公司 | 2018-07-24 | — | — | CN | disclosed |
| CN-105088311-A | Aluminum alloy nickel-free environment-friendly hole sealing agent | SHENZHEN QIANHAI AILIYOU TECHNOLOGY CO LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-101321535-A | Heteroaromatic sulfonamide prodrugs | BAYER SCHERING PHARMA AG (DE) | 2008-12-10 | — | — | CN | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20070135399-A1 | Heteroaromatic sulphonamide prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-14 | — | — | US | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| CN-1295677-A | Method and apparatus for accelerated orthokeratology | EASTA PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135399-A1 | Heteroaromatic sulphonamide prodrugs | SULT2A1, SULT1E1, SULT1A1 | HCAR2 220/4885NAPRT 79/4885ATM 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.